Placebo for Saxagliptin
Sponsors
AstraZeneca, Prof. Dr. Thomas Forst
Conditions
Inadequate Glycaemic ControlType 2 Diabetes MellitusType2 Diabetes Mellitus
Phase 3
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
CompletedNCT02104804
Start: 2014-05-07End: 2016-02-26Updated: 2017-10-02
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
CompletedNCT02681094
Start: 2016-02-26End: 2017-07-15Updated: 2018-10-10
Phase 4
Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
CompletedNCT02304081
Start: 2015-01-31End: 2016-08-31Updated: 2018-06-20
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
CompletedNCT02471404
Start: 2015-09-21End: 2017-03-13Updated: 2019-03-26